Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors

A series of new podophyllotoxin linked β-carboline congeners have been synthesized by coupling various substituted β-carboline acids with 4β-aminopodophyllotoxin. Evaluation of their anticancer activity against a panel of human cancer cell lines such as lung cancer (A549), prostate cancer (DU-145),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2018-01, Vol.144, p.557-571
Hauptverfasser: Sathish, Manda, Kavitha, Botla, Nayak, V. Lakshma, Tangella, Yellaiah, Ajitha, Ayyappan, Nekkanti, Shalini, Alarifi, Abdullah, Shankaraiah, Nagula, Nagesh, Narayana, Kamal, Ahmed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of new podophyllotoxin linked β-carboline congeners have been synthesized by coupling various substituted β-carboline acids with 4β-aminopodophyllotoxin. Evaluation of their anticancer activity against a panel of human cancer cell lines such as lung cancer (A549), prostate cancer (DU-145), MDA MB-231 (breast cancer), HT-29 (colon cancer) and HeLa (cervical cancer) suggested that 7i and 7j are the most cytotoxic compounds with IC50 values of 1.07 ± 0.07 μM and 1.14 ± 0.16 respectively against DU-145 cell line. Further, detailed biological studies such as cell cycle analysis, topoisomerase II inhibition, Comet assay, DNA binding studies and docking studies have revealed that these congeners are DNA interacting topoisomerase II inhibitors. [Display omitted] •A series of podophyllotoxin linked β-carboline congeners were synthesized.•Congeners 7i and 7j were most cytotoxic (1 μM each) on DU-145 cancer cells.•The 7i and 7j were also assayed for DNA topo II inhibition study.•DNA binding studies revealed that these are DNA non intercalators.•All the studies concluded as DNA non intercalating topoisomerase II inhibitors.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2017.12.055